44 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
28 May 24
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
7:09am
at Agios. “This transaction will provide us with the financial independence to prepare for potential PYRUKYND® (mitapivat) launches in thalassemia
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
40% Achieved Transfusion Independence endpoint in open-label Phase 2a study Expect to initiate Phase 2b study of AG-946 in mid-2024 ~75-80k patients
DEFA14A
z78fqbs9
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
59g42 2av
23 Dec 20
Additional proxy soliciting materials
4:52pm
DEFA14A
u4off
21 Dec 20
Additional proxy soliciting materials
5:23pm
DEFA14A
EX-99.1
faq2o8hw
21 Dec 20
Additional proxy soliciting materials
7:10am